Mitomycin C and UFT/leucovorin as salvage treatment in patients with advanced colorectal cancer

Journal of B.U.ON.

Volumn 15, Issue 2, 2010, Pages 270-273

  Michalaki, V ^a   Gennatas, S ^a   Gennatas, Constantine ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Colorectal cancer; Mitomycin C; Salvage therapy; Tegafur

Indexed keywords

FOLINIC ACID; MITOMYCIN C; UFT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER FATIGUE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; SALVAGE THERAPY; TEGAFUR; URACIL;

EID: 77954398798     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Toumigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
2. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic cancer. Irinotecan Study Group. N Engl J Med 2000; 28: 905-914.
3. Glimelius B, Hoffman K, Graf W et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6: 267-274.
4. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988; 22: 333-338.
5. Okabe H, Toko T, Saito H et al. Augmentation of the chemotherapeutic effectiveness of UFT, a combination of tegafur [1-(2-tetrahydrofuryl)-5- fluorouracil] with uracil, by oral 1-leucovorin. Anticancer Res 1997; 17: 157-164.
6. Saltz LB, Leichman CG, Young CW et al. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 1995; 75: 782-785.
7. Laufinan LR, Bukowski RM, Collier MA et al. A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1993; 11: 1888-1893.
8. Ross P, Norman A, Cunningham D et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997; 8: 995-1001. (Pubitemid 27475731)
9. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
10. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10. (Pubitemid 19099520)
11. Douillard JY, Hoff PM, Skillings JR et al. Multicenter phase DI study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3605-3616. (Pubitemid 34983220)
12. Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3617-3627. (Pubitemid 34983221)
13. Pazdur R, Lassere Y, Rhodes V et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994; 12: 2296-2300. (Pubitemid 24346698)
14. Gonzalez Baron M, Feliu J, Garcia Giron C et al. UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience. Oncology 1997; 54 (Suppl 1): 24-29. (Pubitemid 127730738)
15. Borner MM, Schoffski P, de Wit R et al. Patients preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349-358.
16. Leichman CG, Fleming TR, Muggia FM et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995; 13: 1303-1311.
17. Vormittag L, Kornek GV, Gruhsmann B et al. UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis. Anticancer Drugs 2007; 18: 709-712. (Pubitemid 47343665)